Reliable wound care manufacturing for distributors, importers, procurement organisations, and healthcare suppliers across Australia's public and private healthcare sectors.
MARKET OUTLOOK
Australia has one of the Asia-Pacific region's most established wound care markets, supported by an ageing population, high healthcare expenditure, and increasing investment in chronic wound management.
The Australian wound care management devices market is valued at approximately USD 88.2 million in 2026 and is projected to reach USD 119.2 million by 2031, growing at a 6.21% CAGR.
Chronic wounds affect more than 420,000 Australians each year, placing an estimated AUD 3 billion annual burden on the healthcare system.
Advanced wound dressings represent the largest product category, accounting for 35.4% of the market, reflecting continued adoption across hospitals, community healthcare, and aged care services.
USD 88.2M → USD 119.2M
wound care devices market, to 2031
35.4%
share held by advanced wound dressings
Unlike many countries with centralised purchasing, Australia's public healthcare system procures medical devices primarily through state-based procurement organisations. Successful market participation requires suppliers to understand the procurement requirements of individual states and healthcare providers.
HealthShare NSW
HealthShare NSW manages central procurement and supply chain operations for NSW Health, supporting public hospitals, Local Health Districts, and specialist healthcare services. It oversees more than AUD 2.3 billion in annual spending on medical, pharmaceutical, and surgical supplies. Suppliers are typically required to register products through the National Product Catalogue (NPC) and meet Clinical Product Evaluation Registry (CPER) requirements before participating in state procurement programmes.
HealthShare Victoria (HSV)
HealthShare Victoria (HSV) manages collective procurement for Victoria's public health system, administering over AUD 1.5 billion in active purchasing agreements. Victorian public hospitals procure through HSV's centralised contracts, making quality documentation, reliable supply continuity, and compliance with procurement standards essential for supplier qualification.
Queensland Health Procurement
Queensland Health coordinates centralised procurement across the state's Hospital and Health Services (HHS), with wound management and medical consumables representing major purchasing categories. Australian point-of-care data shows that acute wounds account for approximately 40% of treated cases, while leg ulcers, pressure injuries, and diabetic foot ulcers collectively represent nearly 31% of the long-term wound burden.
Australia's wound care market is supported by both publicly funded hospitals and a well-established private healthcare sector.
Public & Private Healthcare
KEY MARKET INSIGHTS INCLUDE:
Public hospitals procure wound care products through consolidated state procurement frameworks.
Private hospital groups, including Ramsay Health Care and Healthscope, continue to expand demand for advanced wound care products used in surgical and specialist care.
Products supplied to the private sector may require inclusion on Australia's Prescribed List of Medical Devices (formerly the Prostheses List) to support reimbursement pathways.
Hospitals account for approximately 39% of wound care market demand, while home healthcare and residential aged care represent the fastest-growing treatment settings.
Australia's ageing population, with more than 16.2% of residents aged 65 years and over, continues to increase demand for diabetic foot ulcer management, pressure injury prevention, venous leg ulcer treatment, and post-operative wound care.
COMPLETE PORTFOLIO
Our wound care portfolio is available for professional healthcare distribution throughout Australia.
HAVE QUESTIONS?
Yes. MEGHdinâ„¢ sterile wound dressings are fully available for Australian healthcare supply. Meghdoot Pharma supports local Australian sponsors and medical distributors with complete regulatory dossiers backed by TGA Class III ARTG inclusion, EN ISO 13485:2016 Quality System Certification (Cert No. QMS-13-010-2021/A), CE Mark Approval (NB 1434), and EU MDR Class III Surveillance (SRN: IN-MF-000011404) to meet state hospital procurement frameworks (such as HealthShare NSW, HSV, and Queensland Health).
Meghdoot Pharma brings over four decades of dedicated medical device manufacturing experience, fully audited Class III regulatory credentials, consistent cleanroom production, competitive direct-from-factory pricing, and responsive B2B supply chain support built for long-term commercial growth.
Hospitals, private healthcare networks, and medical supply procurement teams can purchase MEGHdinâ„¢ through our appointed Australian distribution partners. You can also contact our export division directly to be connected with our authorized supply channels or to discuss bulk commercial purchasing for institutional health networks.
Yes. Qualified Australian healthcare professionals, wound care specialists, and hospital product evaluation committees can request technical product datasheets, clinical literature, and sample evaluation kits directly from our export team to conduct independent product assessments.
Contact our export division directly by phone at (+91) 22 4962 2201 or email mdootmeditex@gmail.com or visit the Contact Page to request commercial quotes, sample evaluation kits, and technical registration documentation for Australia.
Contact our export team to discuss CE-certified wound care products, technical documentation, and distribution opportunities across the Australian healthcare market.
